An Overview of the Allopathic Drug Registration Process and Requirements in Ghana
Abstract
Ghana is one of the most developed countries in the West African region, second only to Ivory Coast. The Food and Drug Authority (FDA) of Ghana regulates the quality, safety, and efficacy of medicinal products. Recently, the government has increased its focus on the healthcare sector, allocating a free zone to promote in-house manufacturing of pharmaceutical products. Drug product registration in Ghana is less complex compared to other developing African countries. Recently, Ghana's National Regulatory Authority (NRA) achieved maturity level 3 according to the WHO GBT scheme. The FDA accepts dossiers in the Common Technical Document (CTD) format as per the ICH guidelines (M4). Additionally, there are special provisions to fast-track the registration process. However, the FDA is still behind in terms of dossier submission via eCTD software, and there is no way to track applications after submission; applicants must visit physically to check the status. Nevertheless, Ghana is continuously improving its processes with the help of the WHO to streamline the registration process. This paper summarizes the process and requirements for the registration of allopathic drugs in Ghana.
Downloads
References
https://www.worldometers.info/world-population/ghana-population/
2. World Bank Group [Internet]. US: WBG; 2024 [cited 2024 Dec 20]. Available from:
https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=GH
3. World Health Organization [Internet]. Switzerland: WHO; 2024 [cited 2024 Dec 20]. Available from:
https://data.who.int/countries/288
4. ReportLinker [Internet]. United States of America: ReportLinker; 2024 [cited 2024 Dec 20]. Available from:
https://www.reportlinker.com/market-report/Pharmaceutical/6257/Pharmaceutical?term=pharma%20industry&matchtype=p&loc_interest=&loc_physical=9069837&gad_source=1&gclid=EAIaIQobChMIt-2n3Ya-iwMV0pxQBh1BqTdnEAAYASAAEgKoPvD_BwE
5. Ghana Commercial Bank [Internet]. Ghana: GCB; 2022 [cited 2024 Dec 20]. Available from:
https://www.gcbbank.com.gh/downloads/research/sector-industry-reports/126-pharmaceutical-industry-in-ghana-2022/file
6. High Commission of India, Ghana [Internet]. Ghana: HCI, Ghana; 2021 [cited 2024 Dec 20]. Available from:
https://www.hciaccra.gov.in/public_files/assets/pdf/1618554652Market%20Access%20Survey%20on%20Pharmaceduitical%20sector%20in%20Ghana.pdf
7. Pharmexcil, [Internet]. India: Pharmexcil; 2020 [cited 2024 December 20]. Available from:
pharmexcil.com/uploads/countryreports/Ghana_Market_Regulatory_report2020.pdf
8. Ndomondo-Sigonda M, Miot J, Naidoo S. Medicines Regulation in Africa: Current State and Opportunities. Pharmaceutical Med. 2017 Nov; 31(6): 383-397. Available from:
https://link.springer.com/content/pdf/10.1007/s40290-017-0210-x.pdf
9. FDA, Ghana [Internet]. Ghana: FDA Ghana; 2012 [cited 2024 Dec 20]. Available from:
https://www.moh.gov.gh/wp-content/uploads/2016/02/Public-Health-Act-851.pdf
10. FDA, Ghana [Internet]. Ghana: FDA Ghana; 2024 [cited 2024 Dec 20]. Available from:
https://fdaghana.gov.gh/
11. Mercy Owusu‑A. Delese Mimi D. Kwame Dei Asamoah O. Samuel Asante‑B. Adem K. Stuart W. Sam S. Evaluation of the Food and Drugs Authority, Ghana Regulatory Review Process: Challenges and Opportunities. Ther Innov Regul Sci. 2023 Mar; 57(2): 372-385. Available from:
https://pmc.ncbi.nlm.nih.gov/articles/pmid/36352343/
12. World Health Organization [Internet]. Switzerland: WHO; 2024 [cited 2024 Dec 20]. Available from:
https://www.who.int/tools/global-benchmarking-tools#:~:text=The%20GBT%20is%20designed%20to,quality%20and%20risk%20management%20system
13. World Health Organization [Internet]. Switzerland: WHO; 2020 [cited 2024 Dec 20]. Available from:
https://www.afro.who.int/news/ghana-foods-and-drugs-authority-fda-attains-maturity-level-3-regulatory-status
14. World Health Organization [Internet]. Switzerland: WHO; 2024 [cited 2024 Dec 20]. Available from:
https://www.who.int/publications/m/item/list-of-nras-operating-at-ml3-and-ml4
15. FDA, Ghana [Internet]. Ghana: FDA Ghana; 2024 [cited 2024 Dec 20]. Available from:
https://fdaghana.gov.gh/wp-content/uploads/2024/10/GUIDELINE-ON-LICENSING-OF-DRUG-MANUFACTURING-FACILITIES.pdf
16. FDA, Ghana [Internet]. Ghana: FDA Ghana; 2024 [cited 2024 Dec 20]. Available from:
https://fdaghana.gov.gh/wp-content/uploads/2024/10/GUIDELINE-ON-THE-GMP-REQUIREMENTS-FOR-DRUG-MANUFACTURING-FACILITIES.pdf
17. FDA, Ghana [Internet]. Ghana: FDA Ghana; 2019 [cited 2024 Dec 20]. Available from:
https://fdaghana.gov.gh/wp-content/uploads/2024/09/WAIVER-REQUIREMENTS-FOR-cGMP-INSPECTIONS-.pdf
18. FDA, Ghana [Internet]. Ghana: FDA Ghana; 2024 [cited 2024 Dec 20]. Available from:
https://fdaghana.gov.gh/services-2/client-service-charter/
19. FDA, Ghana [Internet]. Ghana: FDA Ghana; 2024 [cited 2024 Dec 20]. Available from:
https://fdaghana.gov.gh/approved-fee-schedule/
20. FDA, Ghana [Internet]. Ghana: FDA Ghana; 2024 [cited 2024 Dec 20]. Available from:
https://fdaghana.gov.gh/guidelines-on-registration-of-allopathic-drugs/
21. FDA, Ghana [Internet]. Ghana: FDA Ghana; 2024 [cited 2024 Dec 20]. Available from:
https://fdaghana.gov.gh/guidelines-on-registration-of-allopathic-drugs-quality-part/
22. FDA, Ghana [Internet]. Ghana: FDA Ghana; 2024 [cited 2024 Dec 20]. Available from:
https://fdaghana.gov.gh/quality-overall-summary-product-dossier-qos-pd-template/
23. FDA, Ghana [Internet]. Ghana: FDA Ghana; 2024 [cited 2024 Dec 20]. Available from:
https://fdaghana.gov.gh/guidelines-on-the-registration-of-medicinal-products-classified-for-fast-track-processing/
24. FDA, Ghana [Internet]. Ghana: FDA Ghana; 2024 [cited 2024 Dec 20]. Available from:
https://fdaghana.gov.gh/guidelines-on-stability-testing-of-active-pharmaceutical-ingredients-and-finished-pharmaceutical-products-2/
25. FDA, Ghana [Internet]. Ghana: FDA Ghana; 2024 [cited 2024 Dec 20]. Available from:
https://fdaghana.gov.gh/guidelines-on-conducting-bioequivalence-studies/
26. FDA, Ghana [Internet]. Ghana: FDA Ghana; 2020 [cited 2024 Dec 20]. Available from:
https://fdaghana.gov.gh/guidelines-for-qualified-person-for-pharmacovigilance-3/
27. FDA, Ghana [Internet]. Ghana: FDA Ghana; 2024 [cited 2024 Dec 20]. Available from:
https://fdaghana.gov.gh/guidelines-for-labelling-of-drugs-3/
28. FDA, Ghana [Internet]. Ghana: FDA Ghana; 2024 [cited 2024 Dec 20]. Available from:
https://fdaghana.gov.gh/guidelines-on-naming-of-medicinal-products/
29. FDA, Ghana [Internet]. Ghana: FDA Ghana; 2024 [cited 2024 Dec 20]. Available from:
https://fdaghana.gov.gh/process-flow-and-timelines-for-medicinal-product-registration/
30. FDA, Ghana [Internet]. Ghana: FDA Ghana; 2024 [cited 2024 Dec 20]. Available from:
https://fdaghana.gov.gh/process-flow-and-timelines-for-medicinal-product-fast-tack-registration1/
31. FDA, Ghana [Internet]. Ghana: FDA Ghana; 2024 [cited 2024 Dec 20]. Available from:
https://fdaghana.gov.gh/services-2/product-registration/allopathic-product-registration/
32. FDA, Ghana [Internet]. Ghana: FDA Ghana; 2023 [cited 2024 Dec 20]. Available from:
https://fdaghana.gov.gh/fda-reliance-guideline-on-regulatory-decision-making/
33. FDA, Ghana [Internet]. Ghana: FDA Ghana; 2024 [cited 2024 Dec 20]. Available from:
https://fdaghana.gov.gh/process-flow-and-timelines-for-medicinal-product-re-registration/
34. FDA, Ghana [Internet]. Ghana: FDA Ghana; 2024 [cited 2024 Dec 20]. Available from:
https://fdaghana.gov.gh/process-flow-and-timelines-for-medicinal-product-variation/
35. FDA, Ghana [Internet]. Ghana: FDA Ghana; 2024 [cited 2024 Dec 20]. Available from:
https://fdaghana.gov.gh/guideline-on-variations/
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM
